About this trial
This study aims to evaluate the feasibility, safety, and cost-effectiveness of opportunistic salpingectomy (OS-the removal of the fallopian tubes) at the time of laparoscopic cholecystectomy (the removal of the gallbladder) to prevent ovarian cancer. Ovarian cancer is the fifth leading cause of cancer-related mortality in females in Canada. OS can prevent the most common and lethal type of ovarian cancer, high-grade serous carcinoma (HGSC). OS during gynecologic surgery (hysterectomy or instead of tubal ligation) is safe and effective. However, rates of hysterectomies and tubal sterilization are decreasing. This research team aims to extend the prevention of ovarian cancer by expanding to offer OS during other surgeries in the abdomen, when patients are already undergoing a surgical procedure. This study will examine: 1) the feasibility of OS at the time of laparoscopic cholecystectomy; 2) the safety of OS at the time of laparoscopic cholecystectomy; 3) any health services consequences of offering OBS during laparoscopic cholecystectomy.
The hypothesis is that OS at the time of laparoscopic cholecystectomy is a feasible, safe, and cost-effective primary prevention strategy for ovarian cancer. It is also hypothesized that there will be 10-20 minutes of additional operating room time for completing OS, and that integrating the identified partners and knowledge users, as well as adding relevant knowledge users as the project progresses, will affect the rapid mobilization of our findings.
Eligibility criteria
Qualifiers
Individuals with fallopian tubes who are undergoing lap chole and have more than 24 hours from surgeon consult to surgery, regardless of menopausal status
Age of 35 years and older
Patient must be able to give oral and written informed consent
Premenopausal patients will be included but will be counseled regarding their fertility
Disqualifiers
Less than 24 hours available from surgeon consult to surgery
Individuals with a desire for a future pregnancy
Previously had a salpingectomy or salpingo-oophorectomy
Trial design
Treatments tested in this trial
- Bilateral salpingectomy
- Laparoscopic cholecystectomy
Treatment groups
Sponsors and collaborators
University of British Columbia
Lead sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Canadian Cancer Society (CCS)
Collaborator